A Crystal Structure of the Bifunctional Antibiotic
the canonical TnaC sequence, indicating that even residues unrelated to the stalling process can adopt a distinct conformation within the exit tunnel. This notion is supported by a cryo-EM structure of a yeast 80S ribosome-nascent chain complex stalled during the translation of a truncated dipeptidylaminopeptidase B (DP120) mRNA at 6.1 Å resolution (27) . Although the DP120 sequence has no stalling capacity, density for this nascent chain is visible, indicating a preferred conformation within the exit tunnel (Fig. 4D) . Notably, the DP120 nascent chain follows a different path from that reported here for TnaC (Fig. 4 , E and F). Clearly the chemical and electrostatic properties of the tunnel environment play a pivotal role in facilitating this kind of distinct nascent chain behavior (3, 4) . The finding that nascent chains with little or no sequence conservation interact with the exit tunnel in a distinct manner and adopt individual conformations may be important not only for initial folding events (1-3) but also for the variety of nascent chain-mediated regulatory mechanisms (5 Simocyclinones are bifunctional antibiotics that inhibit bacterial DNA gyrase by preventing DNA binding to the enzyme. We report the crystal structure of the complex formed between the N-terminal domain of the Escherichia coli gyrase A subunit and simocyclinone D8, revealing two binding pockets that separately accommodate the aminocoumarin and polyketide moieties of the antibiotic. These are close to, but distinct from, the quinolone-binding site, consistent with our observations that several mutations in this region confer resistance to both agents. Biochemical studies show that the individual moieties of simocyclinone D8 are comparatively weak inhibitors of gyrase relative to the parent compound, but their combination generates a more potent inhibitor. Our results should facilitate the design of drug molecules that target these unexploited binding pockets.
B
acterial diseases remain a major problem because of the emergence of drug-resistant bacteria combined with the dearth of new antibacterial agents. Despite extensive efforts, there remain relatively few effective drug targets for antibacterials. One of these is the enzyme DNA gyrase, a DNA topoisomerase that controls the topology of DNA (1, 2) . Topoisomerases are classified into two types, I and II, depending on whether they catalyze reactions involving the transient breakage of one or both strands of DNA. Gyrase is the only type II DNA topoisomerase that can catalyze DNA supercoiling; this reaction is driven by the free energy of adenosine triphosphate (ATP) hydrolysis (3) . Gyrase consists of two subunits, GyrA and GyrB (97 kD and 90 kD, respectively, in Escherichia coli), which form an A 2 B 2 complex in the active enzyme. Because gyrase is essential in bacteria and lacking in humans, it is a valuable drug target (4) . The complexity of the gyrase supercoiling reaction presents multiple opportunities for intervention. Two wellknown groups of gyrase-specific antibacterial agents are quinolones and aminocoumarins. Fluoroquinolones, such as ciprofloxacin, are highly successful drugs (5), but their usefulness is diminishing as a consequence of bacterial resistance (6). Aminocoumarins, e.g., novobiocin and clorobiocin, are less successful clinically because of toxicity and solubility issues but are very well characterized in terms of their mode of action on gyrase (7), including several crystal structures (8) (9) (10) (11) . Aminocoumarins act by competitively inhibiting the binding of ATP to the GyrB subunit (11) . The cloning and sequencing of the biosynthetic pathways for the aminocoumarins novobiocin, clorobiocin, and coumermycin A 1 and the application of bioengineering methodologies (12) have enabled the production of a series of modified aminocoumarins with varying potencies against their targets, gyrase and topoisomerase IV (13, 14) . This work has raised the possibility of engineering antibacterial agents targeted to gyrase that are based on natural antibiotics.
Simocyclinone D8 (SD8) was isolated from Streptomyces antibioticus Tü 6040 (15) (16) (17) (18) . The antibiotic consists of a chlorinated aminocoumarin (AC) linked to an angucyclic polyketide (PK) via a tetraene linker and a D-olivose sugar (Fig. 1) . Because of the presence of the AC moiety, the expectation was that SD8 would target the adenosine triphosphatase (ATPase) domain of GyrB. Although SD8 is a potent inhibitor of E. coli gyrase, it does not inhibit the intrinsic GyrB ATPase activity. Instead, SD8 binds to the N-terminal domain of GyrA and prevents DNA binding (19) . In hindsight, this is not surprising because SD8 lacks the decorated noviose sugar that is attached to the 7-OH of the AC ring and is involved in the majority of the interactions with GyrB in other aminocoumarins (8) (9) (10) (11) . In contrast to quinolones and aminocoumarins, which can act on both gyrase and its close relative topoisomerase IV, SD8 is potent against gyrases from E. coli and Staphylococcus aureus but much less effective against topoisomerase IV from these species (20) .
We have crystallized the N-terminal domain of GyrA (GyrA59) complexed with SD8 and determined the crystal structure at 2.6-Å resolution by molecular replacement from the structure of unliganded GyrA59 that was previously determined (21) . Our structure reveals a ligand-stabilized homotetramer of GyrA59 subunits consisting of two A59 dimers cross-linked by four molecules of SD8 (Fig. 2) . The tetraene linker of SD8 acts as an extended rod, about 10 Å long, that holds the AC and PK moieties apart. Each GyrA subunit has distinct pockets that accept the AC and PK groups, respectively, of two separate SD8 molecules; both pockets lie in the predicted DNA binding saddle. Additional lobes of electron density adjacent to the PK moiety have been modeled as Mg 2+ ions (Fig. 3A and fig. S1 ). Although each subunit interacts with two SD8 molecules, because each of these molecules is shared by two subunits from opposing dimers, the stoichiometry remains 1:1, consistent with previous experiments (19) . In addition to the SD8-mediated dimer-dimer interactions, there is about 1500 Å 2 of protein-protein interface. This includes 12 hydrogen bonds, 10 of which involve residues spanning Leu 17 to Asp 23 , a region just before a-helix 1 that was not visible in the original GyrA59 structure (21) . Superposition of the SD8 complex and ligand-free GyrA59 structures gives root mean square deviation values below 1 Å, both for (fig. S2) . Intriguingly, a single SD8 molecule can be modeled in a "bent" conformation such that it bridges between the AC and PK pockets of the same subunit, while maintaining essentially the same contacts with the protein seen in the crystal structure ( fig. S3 ). This places the tetraene linker close to, and possibly interacting with, a-helix 4.
To investigate the oligomeric state in solution, we performed a series of molecular weight (MW) studies. Analytical ultracentrifugation (table S2) showed that the MW of GyrA59 in the absence of SD8 or at low ligand:protein ratios (<~3:1) was 120 kD, suggesting a dimer, whereas at high ligand:protein ratios (>~4:1) GyrA59 had a MW of~250 kD, consistent with a tetramer. By using nanoelectrospray ionization mass spectrometry (nanoESI MS) under conditions where noncovalent interactions are preserved, we assessed the binding of SD8 to GyrA59 and full-length GyrA. In the absence of SD8, both proteins had MWs consistent with dimers ( fig. S4 ). Titration of SD8 into solutions containing the proteins showed dimeric species with either one or two SD8 molecules bound at ligand:protein ratios of <~2:1. With a ligand:protein ratio of 3:1, we began to see formation of a tetrameric species, which increased with increasing SD8 concentrations to become the predominant species at~7.5:1 ( fig. S4) . These experiments showed small amounts of three SD8 molecules bound per dimer but no evidence of four, suggesting that a tetramer readily forms once four molecules are bound ( fig. S4 ). We suggest that the dimeric species, observed at limiting ligand concentrations, might represent a single SD8 molecule bound to the AC and PK pockets within the same subunit ( fig. S3) .
To probe the importance of the two binding pockets, we analyzed the interactions of GyrA59 with simocyclinone analogs lacking either the PK or the AC moiety (Fig. 1) . Simocyclinone C4 is a naturally occurring intermediate in the SD8 pathway that lacks the AC moiety; MGD8N2A, which lacks the PK moiety, was generated by chemical hydrolysis of SD8. The parent compound has a minimum inhibitory concentration (IC 50 ) value of 0.6 mM for inhibition of gyrase supercoiling, whereas IC 50 values of 70 and 50 mM were obtained for analogs lacking either the AC or the PK moiety, respectively (Fig. 1) . Although inhibition is greatly reduced, the fact that these SD8 analogs have some activity suggests that cross-linking of the two GyrA dimers is not a prerequisite for inhibition.
One key issue was to establish the in vivo target of simocyclinones; recent transcriptional profiling studies (20) suggest but do not prove that gyrase is the target. To address this, we selected spontaneous resistant mutants in E. coli. Wild-type E. coli and other Gram-negative bacteria are resistant to simocyclinones because the compounds cannot penetrate the outer membrane (15); we therefore used an E. coli strain (NR698) that is sensitive because it carries an in-frame de- fig. S5 ). These amino acids are close to the bound SD8 molecule in the crystal structure, consistent with gyrase being the in vivo target. Unlike the 22 gyrA mutants, the remaining nine isolates had also acquired resistance to bile salts, suggesting that they could be accounted for by spontaneous second-site mutations that are known to restore outer membrane impermeability to the imp mutant (22) .
On the basis of the spontaneous mutations and the crystal structure information, we made selected site-directed mutations in GyrA to probe its interaction with SD8 in vitro. The mutant proteins, together with wild-type GyrB, were assayed for DNA supercoiling in the presence of SD8 (Table 1) ) pocket showed simocyclinone-resistant supercoiling. SD8 binding to an inactive mutant in the PK pocket, H78A (23) , was investigated by surface-plasmon resonance using the GyrA59 protein. The mutant showed decreased binding affinity for SD8 (K D values were 1.3 mM for wild type and 10.4 mM for H78A) and had a near-identical far-ultraviolet circular dichroism spectrum to wild-type GyrA, suggesting that it was properly folded.
Quinolone-resistant mutations map to both gyrA and gyrB in regions known as the quinoloneresistance determining regions [QRDRs (24, 25) ]. In the case of E. coli GyrA, the QRDR occurs between amino acids 67 and 106 with mutations identified at Ala S5 ). From the published structures of quinolone-DNA cleavage complexes of Streptococcus pneumoniae topo IV (27), we can infer the location of the quinolonebinding site in GyrA, which is adjacent to but not overlapping the SD8 binding sites (Fig. 4) . The quinolones do not make substantive contacts with the topo IV ParC protein, being closest to the equivalents of residues Gly 81 to Ala 84 and Asp 87 in GyrA. Therefore, at least some of the mutations in the QRDR of GyrA most likely have indirect effects on quinolone binding. Given the proximity of the quinolone and SD8 binding sites, we investigated whether there was any crossresistance between the two types of inhibitor. SD8-resistant mutants were tested for their susceptibility to the fluoroquinolone ciprofloxacin, and a range of ciprofloxacin-resistant mutants were tested for their susceptibility to SD8 (Table 1) . Mutations in the simocyclinone-binding pockets (AC and PK) result in near-wild-type amounts of susceptibility to ciprofloxacin (Table 1) ; QRDR mutations in a-helix 4 of GyrA confer increased resistance to both ciprofloxacin and SD8. None of these amino acids makes direct contacts with bound SD8 (Fig. 3B) ; given the low resolution of the quinolone-DNA-topo IV complex structures, it is not possible to precisely define any ligandprotein interactions, but it is likely that substitutions at positions 81 to 84 and 87 in GyrAwould have an effect on drug binding. The prevalence of mutations at Ser 83 and Asp 87 in quinolone-resistant clinical isolates supports this assertion (26) . In the case of SD8, it is possible that mutations in a-helix 4 of GyrA, which lies between the AC and PK binding pockets, can affect the proposed bridging of the two binding sites by the tetraene linker ( fig. S3) .
Given the global concerns over drug-resistant bacterial diseases, work on SD8 raises the prospect of developing agents that exploit its bifunctional mode of antibiotic action on a well-validated target. Alternatively, designing monofunctional compounds with enhanced affinity for one or the other of the binding sites may prove fruitful. (28) . The protein backbones are shown as ribbons and the drug molecules in stick representation, with GyrA59-SD8 in red, ParC-clinafloxacin in green, and the DNA from the latter structure in yellow. For clarity, the ParE subunits have been omitted from 3FOE. The SD8 and clinafloxacin binding sites are adjacent but do not overlap. This figure illustrates how SD8 would interfere with DNA binding; this would also be the case if the drug were bound in the "bent-over" conformation proposed in fig. S3 . The arrow indicates the position of a-helix 4.
